Table 1 CKD stage definition and summary overall and by randomized treatment group per clinical trial*
Study CO405 (%) | Study CO406 (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
CKD stage | eGFR definition† | PGL q2wks | PGL q4wks | Placebo | Overall | PGL q2wks | PGL q4wks | Placebo | Overall |
(n = 43) | (n = 41) | (n = 20) | (n = 104) | (n = 42) | (n = 43) | (n = 23) | (n = 108) | ||
1 | ≥90 | 8 (18.6) | 6 (14.6) | 3 (15.0) | 17 (16.3) | 9 (21.4) | 5 (11.6) | 3 (13.0) | 17 (15.7) |
2 | 60-89 | 14 (32.6) | 12 (29.3) | 4 (20.0) | 30 (28.8) | 12 (28.6) | 19 (44.2) | 13 (56.5) | 44 (40.7) |
3 | 30-59 | 15 (34.9) | 19 (46.3) | 11 (55.0) | 45 (43.3) | 17 (40.5) | 13 (30.2) | 5 (21.7) | 35 (32.4) |
4 | 15-29 | 6 (14.0) | 4 (9.8) | 2 (10.0) | 12 (11.5) | 4 (9.5) | 5 (11.6) | 2 (8.7) | 11 (10.2) |
5 | <15 (or dialysis) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |